![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/impact-therapeutics-entered-into-global-partnership-with-eikon-therapeutics-to-develop-and-commercialize-parp1-selective-inhibitors-301839806.html
https://www.globenewswire.com/news-release/2022/08/19/2501390/0/en/FDA-Granted-Orphan-Drug-Designation-to-IMP4297-TMZ-for-SCLC.html
https://www.prnewswire.com/news-releases/impact-therapeutics-announces-completion-of-series-d1-financing-301501583.html
https://www.globenewswire.com/news-release/2021/11/04/2327097/0/en/Burning-Rock-Collaborates-with-IMPACT-Therapeutics-to-Provide-Testing-Services-in-Developing-IMP9064-in-both-US-and-China.html
https://www.prnewswire.com/news-releases/impact-therapeutics-announced-atr-inhibitor-imp9064-ind-clearance-by-fda-301411723.html
https://www.prnewswire.com/news-releases/impact-therapeutics-appoints-dr-chun-pyn-shen-as-head-of-regulatory-affairs-301388569.html
https://en.prnasia.com/releases/global/impact-therapeutics-announced-first-patient-dose-of-wee1-inhibitor-imp7068-in-the-u-s--310978.shtml
https://www.prnewswire.com/news-releases/impact-therapeutics-announced-first-patient-dose-of-wee1-inhibitor-imp7068-in-the-us-301244572.html
https://www.globenewswire.com/news-release/2020/08/20/2081480/0/en/Junshi-Biosciences-and-Impact-Therapeutics-Establish-Joint-Venture-to-Develop-PARP-Inhibitor-Senaparib-IMP4297-in-China.html